Surveillance for comorbidities during systemic MHT

Review individuals taking systemic MHT at least annually to assess for new or changed comorbidities that would alter the balance of benefits and harms. Check weight, blood pressure, and fasting lipids, and perform breast examination and diabetes screening.

Perform cancer screening as for the general population (eg mammograms, cervical screening tests); see the Population Based Screening Framework.

If a new comorbidity is detected or there is a change in a pre-existing condition, determine if systemic MHT can be adjusted or should be stopped. See Contraindications, benefits and harms of systemic MHT and Systemic MHT in specific patient groups. Seek specialist advice if uncertain about the harm-benefit balance of continuing therapy.